A phase 1 trial has been completed and reported, but a phase 2 trial comparing amn107, or nilotinib, to imatinib (gleevec
), was closed early due to interim analysis showing nonsuperiority.
It is being tried in combo with Gleevec in other trials. Fox chase has a trial. Nccn guidelines accept nilotinib as a treatment option but it's use is still off-label for now in gist.